@article{PAR00015368,
  title = {{E}nterococcus hirae and {B}arnesiella intestinihominis facilitate cyclophosphamide-induced therapeutic immunomodulatory effects},
  author = {{D}aillere, {R}. and {V}etizou, {M}. and {W}aldschmitt, {N}. and {Y}amazaki, {T}. and {I}snard, {C}. and {P}oirier-{C}olame, {V}. and {D}uong, {C}. {P}. {M}. and {F}lament, {C}. and {L}epage, {P}. and {R}oberti, {M}. {P}. and {R}outy, {B}. and {J}acquelot, {N}. and {A}petoh, {L}. and {B}echaref, {S}. and {R}usakiewicz, {S}. and {L}angella, {P}. and {S}okol, {H}. and {K}roemer, {G}. and {E}not, {D}. and {R}oux, {A}. and {E}ggermont, {A}. and {T}artour, {E}. and {J}ohannes, {L}. and {W}oerther, {P}. {L}. and {C}hachaty, {E}. and {S}oria, {J}. {C}. and {G}olden, {E}. and {F}ormenti, {S}. and {P}lebanski, {M}. and {M}adondo, {M}. and {R}osenstiel, {P}. and {R}aoult, {D}idier and {C}attoir, {V}. and {B}oneca, {I}. {G}. and {C}hamaillard, {M}. and {Z}itvogel, {L}.},
  editor = {},
  language = {{ENG}},
  abstract = {{T}he efficacy of the anti-cancer immunomodulatory agent cyclophosphamide ({CTX}) relies on intestinal bacteria. {H}ow and which relevant bacterial species are involved in tumor immunosurveillance, and their mechanism of action are unclear. {H}ere, we identified two bacterial species, {E}nterococcus hirae and {B}arnesiella intestinihominis that are involved during {CTX} therapy. {W}hereas {E}. hirae translocated from the small intestine to secondary lymphoid organs and increased the intratumoral {CD}8/ {T}reg ratio, {B}. intestinihominis accumulated in the colon and promoted the infiltration of {IFN}-gamma-producing gamma delta {T}au cells in cancer lesions. {T}he immune sensor, {NOD}2, limited {CTX}-induced cancer immunosurveillance and the bioactivity of these microbes. {F}inally, {E}. hirae and {B}. intestinihominis specific-memory {T}h1 cell immune responses selectively predicted longer progression-free survival in advanced lung and ovarian cancer patients treated with chemo-immunotherapy. {A}ltogether, {E}. hirae and {B}. intestinihominis represent valuable 'oncomicrobiotics' ameliorating the efficacy of the most common alkylating immunomodulatory compound.},
  keywords = {},
  booktitle = {},
  journal = {{I}mmunity},
  volume = {45},
  numero = {4},
  pages = {931--943},
  ISSN = {1074-7613},
  year = {2016},
  DOI = {10.1016/j.immuni.2016.09.009},
  URL = {https://www.documentation.ird.fr/hor/{PAR}00015368},
}